Johnson & Johnson (NYSE: JNJ) Exec Says Co Expects To File For Regulatory Approval For Lung Cancer Therapy In 2025By legume / October 18, 2023 / JNJ Johnson & Johnson (NYSE: JNJ) Exec Says Co Expects To File For Regulatory Approval For Lung Cancer Therapy In 2025.